Targeting heparanase overcomes chemoresistance and diminishes relapse in myeloma

40Citations
Citations of this article
15Readers
Mendeley users who have this article in their library.

Abstract

In most myeloma patients, even after several rounds of intensive therapy, drug resistant tumor cells survive and proliferate aggressively leading to relapse. In the present study, gene expression profiling of tumor cells isolated from myeloma patients after sequential rounds of chemotherapy, revealed for the first time that heparanase, a potent promoter of myeloma growth and progression, was elevated in myeloma cells that survived therapy. Based on this clinical data, we hypothesized that heparanase was involved in myeloma resistance to drug therapy. In several survival and viability assays, elevated heparanase expression promoted resistance of myeloma tumor cells to chemotherapy. Mechanistically, this enhanced survival was due to heparanasemediated ERK signaling. Importantly, use of the heparanase inhibitor Roneparstat in combination with chemotherapy clearly diminished the growth of disseminated myeloma tumors in vivo. Moreover, use of Roneparstat either during or after chemotherapy diminished regrowth of myeloma tumors in vivo following therapy. These results provide compelling evidence that heparanase is a promising, novel target for overcoming myeloma resistance to therapy and that targeting heparanase has the potential to prevent relapse in myeloma and possibly other cancers.

Cite

CITATION STYLE

APA

Ramani, V. C., Zhan, F., He, J., Barbieri, P., Noseda, A., Tricot, G., & Sanderson, R. D. (2016). Targeting heparanase overcomes chemoresistance and diminishes relapse in myeloma. Oncotarget, 7(2), 1598–1607. https://doi.org/10.18632/oncotarget.6408

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free